Trial Profile
Specific post-marketing surveillance of pazufloxacin (Pasil) Clinical efficacy and safety of pazufloxacin administered at a dose of 1,000 mg twice daily
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Pazufloxacin (Primary)
- Indications Pneumococcal infections; Respiratory tract infections; Sepsis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Toyama Chemical
- 13 Jun 2016 New trial record